Compare GLP & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | NUVB |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2005 | 2020 |
| Metric | GLP | NUVB |
|---|---|---|
| Price | $48.40 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 43.9K | ★ 5.0M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,561,421,000.00 | $62,902,000.00 |
| Revenue This Year | $47.70 | $211.79 |
| Revenue Next Year | $23.62 | $45.15 |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | 8.14 | ★ 698.96 |
| 52 Week Low | $39.58 | $3.92 |
| 52 Week High | $54.29 | $9.75 |
| Indicator | GLP | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 33.93 |
| Support Level | $45.67 | $4.10 |
| Resistance Level | $50.74 | $5.16 |
| Average True Range (ATR) | 1.36 | 0.24 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 50.81 | 33.57 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.